News H. Lundbeck A/S

Equities

HLUN B

DK0061804770

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:59 2024-06-06 am EDT			5-day change	1st Jan Change
36.8 ^DKK	+0.38%		+1.10%	+12.33%

Jun. 03	Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia	CI
May. 15	H LUNDBECK : Q1 beat adds momentum to the recent share price rally

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lundbeck presents innovative first in human trial design of Lu AG13909 for potential treatment of congenital adrenal hyperplasia	Jun. 03	AQ
Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia	Jun. 03	CI
H LUNDBECK : Q1 beat adds momentum to the recent share price rally	May. 15
Transcript : H. Lundbeck A/S, Q1 2024 Earnings Call, May 15, 2024	May. 15
Lundbeck grows strategic brands by +17% CER reaching total revenue of DKK 5.3 billion in the first quarter of 2024	May. 15	AQ
H. Lundbeck A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
H. Lundbeck A/S Provides Earnings Guidance for the Year 2024	May. 15	CI
H LUNDBECK : Lundbeck is well-poised to sail through the transition period	May. 13
Maria Alfaiate appointed new Executive Vice President Commercial and Corporate Strategy at Lundbeck	May. 13	AQ
H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024	May. 13	CI
H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	Apr. 09	MT
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	Apr. 09	AQ
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	Apr. 09	CI
Lundbeck : Articles of Association	Apr. 02	PU
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia	Mar. 27	MT
Abilify Maintena[®] 960 mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia	Mar. 27	AQ
Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia	Mar. 27	CI
Lundbeck held its Annual General Meeting on 20 March 2024 at the company's registered office	Mar. 20	AQ
H. Lundbeck A/S Announces Management Appointments	Mar. 20	CI
H. Lundbeck A/S Approves Dividend for the Accounting Year 2023	Mar. 20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

H LUNDBECK : Q1 beat adds momentum to the recent share price rally

May 15, 2024 at 12:20 pm EDT